Introduction: The aim of the study was to build a model of first failure site-and lesion-specific failure probability after definitive chemoradiotherapy for inoperable NSCLC.
Introduction
Curative-intent chemoradiotherapy has long been the standard of care for patients with inoperable NSCLC. 1 unsatisfactory at around 15%. 2, 3 The natural course of disease depends on histologic type, with adenocarcinoma (AC) metastasizing to the brain more often than squamous cell carcinoma (SCC). [4] [5] [6] [7] Nevertheless, AC and SCC are often lumped together as NSCLC in clinical trials or treatment guidelines.
The Union for International Cancer Control TNM classifications 8, 9 provide important prognostic information. However, when deciding on a combination of systemic and local therapies, estimating the risk of locoregional versus distant recurrence separately would be of obvious clinical interest. Other factors such as tumor volume and number of fludeoxyglucose positron emission tomography (FDG-PET)-positive lymph nodes have been proposed to improve the pretreatment prognostic assessment. 10, 11 Clinical radiotherapy (RT) trials have tested dose escalation to the primary lung tumor in an attempt to improve local control and, in turn, OS. However, the large RTOG 0617 randomized trial 12 found no clinical benefit in the dose escalation arm, emphasizing that local intensification may not be a viable strategy for all patients with NSCLC. Improved knowledge of the most likely failure sites within a patient may be of relevance for further individualization of treatment options in the future.
The aim of the current study was to establish a model of the failure patterns on a patient and lesion level by using baseline clinical data and FDG-PET/computed tomography (CT) scans.
Materials and Methods

Patients
Data were retrospectively retrieved from medical records and archived scans from consecutive patients who received a diagnosis of inoperable, locally advanced NSCLC and were treated at Rigshospitalet, Copenhagen University Hospital from January 2009 to February 2015. In this period, operability was determined according to clinical stage below IIIAN2, comorbidity of the patient, and lung function by a multidisciplinary tumor board consisting of pulmonologists, thoracic surgeons, and medical/radiation oncologists. Patients received definitive chemoradiotherapy or RT alone. Chemotherapy was given either sequentially before radiation or concomitantly with the first cycle of chemotherapy before the PET/CT planning scan. Chemotherapy regimens consisted of either cisplatin/vinorelbin or carboplatin/vinorelbin in a 3-week schedule, given three to six times. Patients who had prior early-stage lung cancer treated with surgery but were now candidates for concomitant chemotherapy and radiotherapy were also included in the study. This could, for example, be due to relapse in a lymph node station or a new primary tumor. These patients were restaged according to the seventh TNM classification from the Union for International Cancer Control. 8 
FDG-PET
In preparation for RT planning, an FDG-PET/CT scan was performed on a Siemens Biograph mCT (Siemens Healthineers, Erlangen, Germany) on a flat table top in treatment position approximately 60 minutes after FDG injection (4 MBq/kg). An iodine-based contrast medium was injected intravenously during the CT scan according to departmental guidelines. Details on PET and CT data acquisition from our institution have been published previously. 13 A maximum of five lesions per patient were evaluated (two tumor sites [T sites]/three lymph node sites [N sites]). If a patient had multiple FDG-avid lesions, the five lesions with the highest FDG uptake and the largest diameter were chosen. FDG-avid lesions were contoured with region of interest (ROI) drawn semiautomatically by using a threshold of 50% of the maximum standardized uptake value (SUV max ). SUV max , SUV peak , mean SUV, and volume (in cm 3 ) were calculated for all individual FDG-positive lesions. SUV peak was defined according to the Positron Emission Tomography Response Criteria in Solid Tumors criteria 14 as a sphere of 1 cm 3 centering on the hottest point in the lesion. The total lesion glycolysis was defined as volume times mean SUV. If a primary tumor (T site) could not be separated from affected lymph nodes (N site), the lesion was analyzed as a T-site lesion. Data from the PET scan were analyzed on a Mirada XD workstation, version 1.1.0.31 (Mirada Medical, Oxford, UK).
RT
RT was given in 2-Gy fractions at five fractions per week for a total of 60 to 66 Gy. Three-dimensional conformal (until January 2014) or volumetric modulated arc therapy planning techniques were applied and based on the midventilation phase of a four-dimensional CT scan. 15 Cone beam CT with tumor match were used for daily image guidance.
The study was approved by the Danish Health and Medicines Authority (case No. 3-3013-569/1/), and it complied with national data protection regulations. According to Danish law, no research ethics approval was necessary because of the retrospective nature of the study.
chi-square test was used to test for associations between two categorical variables ( Table 1) .
Date of histologic examination-confirmed diagnosis was used as the start date, and the dates of imaging (CT, FDG PET, or magnetic resonance scans) confirming a relapse/progression were used as failure dates. The time interval between the start date and the earliest radiologically confirmed treatment failure was termed time to first failure (TFF). Patients alive with no evidence of disease (NED) were censored at the last follow-up in the clinic. OS and TFF data was analyzed by using Kaplan-Meier plots 16 and univariate Cox regression. IBM SPSS Statistics for Windows, version 21.0 (IBM Corp., Armonk, NY) was used for these analyses.
First site of failure was specified as T-site local failure, N-site regional failure, distant metastasis (DM), and either extracranial DM (ECDM) or intracranial DM (ICDM). Failure within the thorax but outside the RT planning target volume (PTV) was scored as ECDM. In case of synchronous local and distant failure, the patient was scored as failing distantly (ECDM or ICDM). Patients with locoregional failure (LRF) were scored on a lesion level regarding T-versus N-site lesions, and the lesion SUV peak value from the RT planning scan was calculated for subsequent statistical analysis.
Failure sites in AC and SCC were compared in univariate competing risk modeling. The cuminc function of the CMPRSK package (version 2.2.7) was used to compare the groups with Fine and Gray's test.
A statistical plan was made before the multivariate Cox regression analysis. Coding and variables are listed in Table 2 . The variables were preselected to reflect a parsimonious list of clinical prognosticators. Subsequent to data collection, changes were made by excluding total lesion glycolysis measures because of a strong correlation with gross tumor volume (GTV) and SUV peak , yielding unstable models ( Supplementary  Fig. 1 ). SUV peak was chosen before seeing the data because of its use in the Positron Emission Tomography Response Criteria in Solid Tumors guidelines.
14 Also, smoking status in pack-years was excluded, as there was no sign of prognostic value (log-rank p ¼ 0.43 for trend between tertiles) in the current data set. The exclusion of smoking status avoided the complication of imputing six cases with missing data on smoking history.
In all cases, the model was stratified for the use of concomitant platinum-based chemotherapy. In multivariate modeling, ECDM and ICDM were combined as DM for power and interpretability of the electronic nomogram. Cause-specific Cox multivariate regression was performed by using the CSC function of the RiskRegression package, version 1.4.3 in R. 17 
Lesion Level Analysis
Multivariable logistic regression analysis was applied to all lesions in patients with known LRF. Two variables on lesion-specific outcome were included in the analysis: SUV peak and tumor versus node (TvsN) (categorical
where P is the probability of being first site of failure in the group of patients with known LRF. We interpret P as the conditional failure probability of a lesion given LRF. This conditional failure probability, P, is subsequently multiplied by the absolute risk of LRF from the competing risk analysis to yield individual lesion failure risk at RT planning PET/CT. Thus, the probability of lesion failure, predicted at the time of RT planning, is calculated by multiplying P times the risk of LRF after 24 months according to the competing risk model. Model calibration was assessed by plotting the lesion predicted probability against observed probability in eight quantiles.
The risk models were published as web applications 18 at http://bit.ly/LungModel, http://bit.ly/ LungModelGTV, and http://bit.ly/LungModelFDG by using the R statistical software package shiny. We used logistic regression of observed failures versus predicted risk of lesion failure to estimate the uncertainty of predictions and provide plus or minus 1.96 times the SE of the logistic fit as estimate of the uncertainty of the lesion failure probability in the web applications.
Results
Treatment Response and Follow-up
In this retrospective study, 251 of 376 patients screened were included. The eligibility criteria were retrievable RT planning PET/CT scans (five patients excluded); receipt of curative-intent RT (39 patients excluded); available medical records (15 patients excluded); AC or SCC histologic type (49 patients excluded), and FDG PET-positive lesions to analyze (17 patients excluded). Patient characteristics are shown in Table 1 .
Missing data were handled as follows. Performance status was missing in seven patients but could be retrospectively assessed from electronic file information. GTV was missing in two patients. A specialist in lung cancer radiology contoured these GTVs retrospectively. Of the 18 patients who had initial stage IV disease, 11 had M1a disease. These lesions received curative-intent RT. Five patients had brain metastases that were either a Thirteen patients without SUV uptake in T site (10 underwent video-assisted thoracoscopic surgery) and 3 had no primary tumor. Patients who underwent video-assisted thoracoscopic surgery before definitive radiotherapy with no SUV peak values in their T sites are listed with their T stage before surgery. b In the case of multiple T-site or N-site lesions, the highest value of SUV peak was chosen. AC, adenocarcinoma; SCC, squamous cell carcinoma; UICC, Union for International Cancer Control; GTV, gross tumor volume; PTV, planning target volume; MLD, mean lung dose; SUV, standardized uptake value; SUV peak , peak standardized uptake value; T site, tumor site; N site, lymph nodes; TLG, total lesion glycolysis.
surgically removed or had stereotactic RT before curative-intent therapy of the lung lesions. Two patients had M1b disease due to metastases to (1) the adrenal gland and (2) a target in the left breast region. These targets were treated with a stereotactic dose and up to 34 Gy, respectively. Outliers in patient characteristics were age with AC having a larger fraction of younger patients than age with SCC. T stage also showed a slight imbalance between the groups ( Supplementary Figs. 2  and 3 ). Three patients relapsed in new lymph nodes inside the thorax but outside the PTV. Six patients failed locoregionally, with LN failure outside the thorax (neck, axilla, and below the diaphragm). These nine patients were coded with ECDM as first site of failure.
Seven patients relapsed inside the thorax but outside the PTV (e.g., contralateral lung [M1a] disease) and were coded with ECDM. Two of them had other DMs (bone and pleura). Seven T-site failures and four N-site failures also failed in distant sites and were scored as DMs (see Supplementary Table 1 for the distribution of first failure sites in AC versus in SCC).
The median time from diagnosis to first relapse was 10.5 months and the median time from first relapse to death was 6 months. The median OS was 18 months for the whole group of 251 patients, with no difference between the two histologic type groups (HR ¼ 0. 
Competing Risk Analysis
Competing risk analysis found a strong association between relapse patterns and histologic type. AC had a lower risk of LRF than did SCC (HR ¼ 0.45, 95% CI: 0.26-0.76, p ¼ 0.003). The risk of failing distantly was twice as high in the AC group (HR ¼ 2.21, 95% CI ¼ 1.41-3.48, p < 0.001) ( Table 2 ). Figure 1 shows the risk of various first-failure types from the competing risk model. The risk of an event increased with time, but there was no major change in risk from 2 to 3 years because most failures occurred within the first 24 months. Stacked patient level outcome by Fine and Grey test showed AC to have higher rates of ICDM (p ¼ 0.00014) and ECDM (p ¼ 0.04) than SCC did. SCC tended to fail locoregionally more often than AC (p ¼ 0.0002). There was no difference in death with NED (p ¼ 0.18) (see Fig. 2 ).
Lesion Risk Assessment
Among the 251 patients, 517 lesions were registered with FDG PET uptake from the RT planning PET/CT scan. In all, 76 lesions (15%) failed in local or regional sites, with 60 T-site failures and 16 N-site failures. Logistic regression showed SUV peak and TvsN to be predictors of lesion failure. T-site lesions were more than 12 times more likely to fail than N-site lesions (OR ¼ 12.8, 95% CI: 5.10-32.17, p 0.0001). Increasing SUV peak was associated with an increased likelihood of lesion failure (OR ¼ 1.26, 95% CI: 1.12-1.40, p < 0.0001).
We found and analyzed 245 FDG-avid lymph nodes, up to three lymph nodes per patient. Of these FDG-avid N-site lesions, 168 lesions (68.6%) were proved by biopsy to be malignant. Lymph node stations 4, 7, and 10 were predominantly represented. A total of 20 N-site lesions with corresponding positive biopsy results relapsed. In all, 238 patients with a total of 493 lesions were included in the overall predicted lesion failure probability analysis. Thirteen patients with no T-site lesion but with 24 nodal lesions were excluded from this analysis. Figure 3 illustrates two patients with different histologic types and thus the difference in lesion failure assessment based on the combined lesion failure probability analysis. A lesion model check was performed and showed agreement between calculated risk and actual failure on a lesion level (Fig. 4) .
Discussion
We developed a competing risk model able to estimate the patient level risk of LRF, DM, and death with NED. Further, the radiation target was subdivided in individual lesions, and the model was able to predict the lesion level risk of failure in the current data set. Competing risk analysis showed that histologic type was the strongest predictor for LRF versus DM failure. We found T-versus N-site and SUV peak to be predictive of lesion-specific outcome in addition to the patient-level prognostics. Internal consistency of the model was examined, and we found reasonable agreement between predicted lesion failure probability and actual lesion failure in calibration plots.
It is of importance that the model be used only for decision support and be read with caution. Results from the model are generated under the assumption that all clinical targets, T sites and N sites, are given a homogeneous normofractionation scheme of 2-Gy fractions 30 to 33 times (five fractions per week for a total of 60 to 66 Gy). It should be stressed that an estimate of low risk of lesion failure does not indicate that it is safe to reduce the dose or otherwise compromise radiation delivery to that lesion.
Nevertheless, our results illustrate the importance of differentiating patients with AC from those with SCC because they have different relapse patterns. The aggregate term NSCLC may not be helpful in advancing the field.
There are numerous reports of the prognostic value of SUV max of the primary lesion, and overall cutoff values have been suggested to define good versus poor prognosis. [19] [20] [21] [22] The lack of external validation should be acknowledged as a limitation of the current study. A number of externally validated prognostic models for overall survival have been published (see, for example, predictcancer.org). Failure site prognostication as in the current study potentially has, if externally validated, additional clinical interest.
We have previously found support for early lesionspecific PET response (DSUV peak ) after one series of chemotherapy to be predictive of failure site in TvsN sites. 13 A decrease in FDG uptake in both tumor and lymph nodes after RT was also found to be a prognostic factor for survival and recurrence. 23 Looking at subvolumes within the original T site, other authors have found that high SUV values could identify areas at high risk for local failure. 24, 25 This led to studies investigating dose escalation to these areas in the hope of achieving a better local tumor control. 26, 27 When analyzing FDG uptake in lymph nodes, 28 a risk of false-positive findings must be taken into consideration. The rate of false-positive lymph node lesions cannot be extracted from our data. SUV measurements vary by blood glucose levels, acquisition modes, and reconstruction algorithms of the PET scans, which makes it hard to reproduce data and Figure 3 . Illustration of two patients and their lesion failure probabilities. Adenocarcinoma (AC): primary tumor in right lung, predicted failure probability ¼ 20% (9 to 31%). Lymph node metastasis in mediastinum, predicted failure probability ¼ 2% (0 to 5%). Squamous cell carcinoma (SCC): primary tumor in left lung, predicted failure probability ¼ 42% (28 to 56%). Lymph node metastasis in mediastinum, predicted failure probability ¼ 12% (9 to15%). 
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First Failure Site after Chemoradiationdefine a definitive cutoff value that is prognostic of outcome in a population with cancer. An external validation of our findings should be conducted to confirm the rationale in differentiating between histologic groups and lesion characteristics, and a prospective study could ideally validate our findings of lesion-specific risk prediction. Improved estimates of the probability of these competing risks will allow individual treatment approaches that would target the patient's most likely failure type if managed with current standard therapy. The need for such personalized patient selection is particularly evident after the impairment in survival observed for patients in the experimental RT arm of RTOG0617, 12 possibly because of excess mortality as a result of the aggressive local treatment intensification. Future randomized trials of local RT intensification are encouraged to distinguish between histologic type and risks of competing events upon inclusion.
In conclusion, AC and SCC of the lung differ in patterns of first failure site after definitive chemoradiotherapy. Competing risk estimates of DM, LRF, and death with NED were generated. Moreover, it was possible to estimate risk of failure in sublesions of the radiation target on the basis of lesion site, SUV peak , and patient-level clinical variables.
